Review of current clinical management guidelines for COVID-19 with special reference to India.
Identifieur interne : 000C51 ( Main/Corpus ); précédent : 000C50; suivant : 000C52Review of current clinical management guidelines for COVID-19 with special reference to India.
Auteurs : Rohit Kumar ; Kutty Sharada Vinod ; Ankit Mittal ; Shreya Das Adhikari ; Nitin GuptaSource :
- Drug discoveries & therapeutics [ 1881-784X ] ; 2020.
English descriptors
- KwdEn :
- Anticoagulants (therapeutic use), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (pathogenicity), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (immunology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Host Microbial Interactions (MeSH), Humans (MeSH), Immunization, Passive (MeSH), Immunologic Factors (therapeutic use), India (epidemiology), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (immunology), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Practice Guidelines as Topic (standards), Practice Patterns, Physicians' (standards), SARS-CoV-2 (MeSH), Steroids (therapeutic use).
- MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , therapeutic use : Anticoagulants, Antiviral Agents, Immunologic Factors, Steroids.
- geographic , epidemiology : India.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- standards : Practice Guidelines as Topic, Practice Patterns, Physicians'.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Host Microbial Interactions, Humans, Immunization, Passive, Pandemics, SARS-CoV-2.
Abstract
The healthcare sector has been overwhelmed by the global rise in the number of COVID-19 cases. The primary care physicians at the forefront of this pandemic are being provided with multiple guidelines (state, national, international). The aim of this review was to examine the existing guidelines for congruence and critically analyze them in light of current evidence. A discordance was noted between the national and state guidelines with respect to indication, duration and dosage of antivirals, steroids/immunomodulators, anticoagulation and convalescent plasma. The lack of concordance between various guidelines mandates the need for a unified national guideline that is regularly updated.
DOI: 10.5582/ddt.2020.03059
PubMed: 32908072
Links to Exploration step
pubmed:32908072Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Review of current clinical management guidelines for COVID-19 with special reference to India.</title><author><name sortKey="Kumar, Rohit" sort="Kumar, Rohit" uniqKey="Kumar R" first="Rohit" last="Kumar">Rohit Kumar</name><affiliation><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Vinod, Kutty Sharada" sort="Vinod, Kutty Sharada" uniqKey="Vinod K" first="Kutty Sharada" last="Vinod">Kutty Sharada Vinod</name><affiliation><nlm:affiliation>Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Mittal, Ankit" sort="Mittal, Ankit" uniqKey="Mittal A" first="Ankit" last="Mittal">Ankit Mittal</name><affiliation><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Adhikari, Shreya Das" sort="Adhikari, Shreya Das" uniqKey="Adhikari S" first="Shreya Das" last="Adhikari">Shreya Das Adhikari</name><affiliation><nlm:affiliation>Departments of Oncoanaesthesia and Palliative Medicine, Dr Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Gupta, Nitin" sort="Gupta, Nitin" uniqKey="Gupta N" first="Nitin" last="Gupta">Nitin Gupta</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32908072</idno><idno type="pmid">32908072</idno><idno type="doi">10.5582/ddt.2020.03059</idno><idno type="wicri:Area/Main/Corpus">000C51</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Review of current clinical management guidelines for COVID-19 with special reference to India.</title><author><name sortKey="Kumar, Rohit" sort="Kumar, Rohit" uniqKey="Kumar R" first="Rohit" last="Kumar">Rohit Kumar</name><affiliation><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Vinod, Kutty Sharada" sort="Vinod, Kutty Sharada" uniqKey="Vinod K" first="Kutty Sharada" last="Vinod">Kutty Sharada Vinod</name><affiliation><nlm:affiliation>Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Mittal, Ankit" sort="Mittal, Ankit" uniqKey="Mittal A" first="Ankit" last="Mittal">Ankit Mittal</name><affiliation><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Adhikari, Shreya Das" sort="Adhikari, Shreya Das" uniqKey="Adhikari S" first="Shreya Das" last="Adhikari">Shreya Das Adhikari</name><affiliation><nlm:affiliation>Departments of Oncoanaesthesia and Palliative Medicine, Dr Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Gupta, Nitin" sort="Gupta, Nitin" uniqKey="Gupta N" first="Nitin" last="Gupta">Nitin Gupta</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Drug discoveries & therapeutics</title><idno type="eISSN">1881-784X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (pathogenicity)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Host Microbial Interactions (MeSH)</term><term>Humans (MeSH)</term><term>Immunization, Passive (MeSH)</term><term>Immunologic Factors (therapeutic use)</term><term>India (epidemiology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (therapy)</term><term>Pneumonia, Viral (virology)</term><term>Practice Guidelines as Topic (standards)</term><term>Practice Patterns, Physicians' (standards)</term><term>SARS-CoV-2 (MeSH)</term><term>Steroids (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term><term>Antiviral Agents</term><term>Immunologic Factors</term><term>Steroids</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Practice Guidelines as Topic</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Host Microbial Interactions</term><term>Humans</term><term>Immunization, Passive</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The healthcare sector has been overwhelmed by the global rise in the number of COVID-19 cases. The primary care physicians at the forefront of this pandemic are being provided with multiple guidelines (state, national, international). The aim of this review was to examine the existing guidelines for congruence and critically analyze them in light of current evidence. A discordance was noted between the national and state guidelines with respect to indication, duration and dosage of antivirals, steroids/immunomodulators, anticoagulation and convalescent plasma. The lack of concordance between various guidelines mandates the need for a unified national guideline that is regularly updated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32908072</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1881-784X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Drug discoveries & therapeutics</Title><ISOAbbreviation>Drug Discov Ther</ISOAbbreviation></Journal><ArticleTitle>Review of current clinical management guidelines for COVID-19 with special reference to India.</ArticleTitle><Pagination><MedlinePgn>171-176</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5582/ddt.2020.03059</ELocationID><Abstract><AbstractText>The healthcare sector has been overwhelmed by the global rise in the number of COVID-19 cases. The primary care physicians at the forefront of this pandemic are being provided with multiple guidelines (state, national, international). The aim of this review was to examine the existing guidelines for congruence and critically analyze them in light of current evidence. A discordance was noted between the national and state guidelines with respect to indication, duration and dosage of antivirals, steroids/immunomodulators, anticoagulation and convalescent plasma. The lack of concordance between various guidelines mandates the need for a unified national guideline that is regularly updated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinod</LastName><ForeName>Kutty Sharada</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Ankit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adhikari</LastName><ForeName>Shreya Das</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Departments of Oncoanaesthesia and Palliative Medicine, Dr Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Nitin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Drug Discov Ther</MedlineTA><NlmUniqueID>101493809</NlmUniqueID><ISSNLinking>1881-7831</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076662" MajorTopicYN="N">Host Microbial Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 19</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">dexamethasone</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32908072</ArticleId><ArticleId IdType="doi">10.5582/ddt.2020.03059</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32908072
|texte= Review of current clinical management guidelines for COVID-19 with special reference to India.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32908072" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |